eTable1 T-cell/B-cell flowcytometry panel

CD3 T cells

CD4 helper T cells

CD19 B cells (from pro-B to blastoid B)

CD27 memory B

CD45R/B220 B cells (all developmental stages

from pro-B through mature B)

CD38 Plasmablasts, transitional B cells

CD180 naïve B cells, memory B cells

CD185 (CXCR5) Follicular helper T (Tfh) cells, mature B cells

CD268 (BAFF-R) mature B cells

CD278 (ICOS), CD279 (PD-1) Activated T cells (Tfh cells, regulatory T cells)

|  |  |  |
| --- | --- | --- |
|  |  | ***eTable 2 MG thymuses and Demographic/Clinical Information*** |
| 　 | 　 | 　 | 　 | 　 |  | Before thymectomy |  | 1 year after thymectomy |
| 　 | Age, y | Gender | Histology | Duration, m | IS therapy | IS duration, m | MGFA | MG-ADL | Ab titer | MGFA | MG-ADL | Ab titer |
| MG1 | 39 | F | Involuted | 24 | None | - | 1 | 4 | 16 | 1 | 1 | 12 |
| MG2 | 59 | F | Involuted | 20 | PSL | 3 | 3b | 10 | 54 | 2b | 6 | NE |
| MG3 | 46 | F | Involuted | 38 | PSL | 2 | 3a | 10 | 1700 | 2b | 8 | 440 |
| MG4 | 26 | F | Involuted | 17 | PSL, Tacrolimus | 8 | 2b | 0 | 1 | NE | NE | NE |
| MG5 | 26 | F | Involuted | 7 | PSL | 3 | 3a | 4 | 5.6 | 2a | 0 | 1.9 |
| MG6 | 58 | F | Involuted | 3 | PSL | 2 | 1 | 1 | 26 | NE | 0 | 7.2 |
| MG7 | 26 | F | Involuted | 17 | PSL, Tacrolimus | 1 | 2b | 1 | 6.6 | 1 | 1 | 2.5 |
| MG8 | 21 | F | Involuted | 25 | PSL, Ciclosporin | 20 | 2b | 2 | 370 | NE | 0 | 130 |
| MG9 | 71 | F | Involuted | 5 | PSL, Tacrolimus | 1 | 2a | 3 | 7.9 | 2a | 3 | 0.9 |
| MG10 | 56 | F | Hyperplasia | 5 | None | - | 3a | 8 | 14 | 1 | 2 | 0.9 |
| MG11 | 11 | F | Hyperplasia | 108 | Tacrolimus | Unknown | 1 | 3 | 2 | NE | NE | NE |
| MG12 | 29 | F | Hyperplasia | 15 | PSL | 10 | 2a | 8 | 270 | 2a | 3 | 7.5 |
| MG13 | 14 | F | Hyperplasia | 24 | PSL | 5 | 2b | 7 | 12 | 2b | 3 | 7.5 |
| MG14 | 25 | F | Hyperplasia | 48 | PSL | 6 | 2a | 6 | 120 | 2b | 2 | 54 |
| MG15 | 57 | F | Thymoma (AB) | 3 | None | - | 2a | 1 | 18 | 2a | 1 | 21 |
| MG16 | 37 | M | Thymoma (B1) | 1 | None | - | 1 | 1 | 0.9 | 2a | 2 | 3.2 |
| MG17 | 65 | F | Thymoma (B2) | 8 | None | - | 2a | 5 | 130 | NE | 2 | 51 |
| MG18 | 40 | F | Thymoma (B2) | 81 | None | - | 2a | 1 | 10 | NE | NE | NE |
| MG19 | 40 | M | Thymoma (B2) | 15 | PSL | 2 | 2b | 2 | 18.5 | 1 | 1 | NE |
| MG20 | 52 | F | Thymoma (B2) | 26 | PSL, Tacrolimus | 4 | 2b | 1 | 290 | NE | NE | NE |
| MG21 | 53 | F | Thymoma (B2) | 1 | None | - | 1 | 2 | 9.7 | NE | 0 | 8.5 |
| MG22 | 56 | M | Thymoma (B3) | 3 | None | - | 2b | 2 | 20 | 0 | 0 | 6.7 |
| MG23 | 68 | F | Thymoma (B3) | 2 | None | - | 1 | 3 | 3.9 | 1 | 2 | 0.8 |
| MG24 | 50 | F | Thymoma (B3) | 6 | PSL | 4 | 1 | 1 | 54 | NE | 4 | 110 |
| MG25 | 60 | F | Thymoma (U) | 12 | None | - | 1 | 3 | 9 | 2b | 2 | NE |

Age = age at thymectomy

Thymoma (WHO classification), U = unclassified

Duration = period between disease onset and thymectomy

IS = immunosuppressive, PSL = prednisolone

Ab = anti-acetylcholine receptor (AChR) antibody (normal < 0.2nmol/L)

MGFA = Myasthenia Gravis Foundation of America

NE = not examined